Growth Metrics

Integra Lifesciences Holdings (IART) Convertible Debt (2016 - 2026)

Integra Lifesciences Holdings' Convertible Debt history spans 16 years, with the latest figure at $83.5 million for Q3 2025.

  • On a quarterly basis, Convertible Debt rose 14.7% to $83.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $83.5 million, a 14.7% increase, with the full-year FY2024 number at $108.1 million, down 81.04% from a year prior.
  • Convertible Debt hit $83.5 million in Q3 2025 for Integra Lifesciences Holdings, down from $108.8 million in the prior quarter.
  • Over the last five years, Convertible Debt for IART hit a ceiling of $571.0 million in Q1 2024 and a floor of $72.8 million in Q3 2024.
  • Historically, Convertible Debt has averaged $345.0 million across 5 years, with a median of $562.2 million in 2021.
  • Biggest five-year swings in Convertible Debt: skyrocketed 22677.04% in 2021 and later crashed 87.22% in 2024.
  • Tracing IART's Convertible Debt over 5 years: stood at $564.4 million in 2021, then rose by 0.52% to $567.3 million in 2022, then increased by 0.51% to $570.3 million in 2023, then plummeted by 81.04% to $108.1 million in 2024, then decreased by 22.76% to $83.5 million in 2025.
  • Business Quant data shows Convertible Debt for IART at $83.5 million in Q3 2025, $108.8 million in Q2 2025, and $102.1 million in Q1 2025.